Literature DB >> 17276782

The eye in hypertension.

Tien Yin Wong1, Tien Wong, Paul Mitchell.   

Abstract

Hypertension has a range of effects on the eye. Hypertensive retinopathy refers to retinal microvascular signs that develop in response to raised blood pressure. Signs of hypertensive retinopathy are frequently seen in adults 40 years and older, and are predictive of incident stroke, congestive heart failure, and cardiovascular mortality--independently of traditional risk factors. Hypertension is also a major risk factor for the development of other retinal vascular diseases, such as retinal vein and artery occlusion, and ischaemic optic neuropathy. High blood pressure increases the risk of both development of diabetic retinopathy and its progression. Adequate control of blood pressure has been proven in randomised clinical trials to reduce vision loss associated with diabetic retinopathy. Finally, hypertension has been implicated in the pathogenesis of glaucoma and age-related macular degeneration. Recognition of the ocular effects of blood pressure could allow physicians to better manage patients with hypertension, and to monitor its end-organ effects.

Entities:  

Mesh:

Year:  2007        PMID: 17276782     DOI: 10.1016/S0140-6736(07)60198-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  147 in total

1.  [Systemic cardiovascular risk assessment. Conventional or eye fundus-based?].

Authors:  A Wolf; M Kernt; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2010-09       Impact factor: 1.059

2.  Associations between dietary flavonoids and retinal microvasculature in older adults.

Authors:  Bamini Gopinath; Gerald Liew; Joshua R Lewis; Nicola P Bondonno; Catherine P Bondonno; George Burlutsky; Jonathan M Hodgson; Paul Mitchell
Journal:  Eur J Nutr       Date:  2019-11-25       Impact factor: 5.614

3.  Retinal vascular caliber and risk of dementia: the Rotterdam study.

Authors:  F J de Jong; E M C Schrijvers; M K Ikram; P J Koudstaal; P T V M de Jong; A Hofman; J R Vingerling; M M B Breteler
Journal:  Neurology       Date:  2011-02-02       Impact factor: 9.910

4.  Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study.

Authors:  Focke Ziemssen; Qi Zhu; Swaantje Peters; Salvatore Grisanti; Mohammed El Wardani; Peter Szurman; Karl U Bartz-Schmidt; Tjalf Ziemssen
Journal:  Int Ophthalmol       Date:  2008-04-17       Impact factor: 2.031

5.  [Hypertensive changes of the fundus].

Authors:  W Göbel; J Matlach
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

6.  Reduced regional cerebral blood flow in patients with heart failure.

Authors:  Bhaswati Roy; Mary A Woo; Danny J J Wang; Gregg C Fonarow; Ronald M Harper; Rajesh Kumar
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

7.  Hypertension genes and retinal vascular calibre: the Cardiovascular Health Study.

Authors:  C Sun; J J Wang; F M Islam; S R Heckbert; R Klein; D S Siscovick; B E K Klein; T Y Wong
Journal:  J Hum Hypertens       Date:  2009-01-15       Impact factor: 3.012

8.  Relative importance of systemic determinants of retinal arteriolar and venular caliber: the atherosclerosis risk in communities study.

Authors:  Gerald Liew; A Richey Sharrett; Jie Jin Wang; Ronald Klein; Barbara E K Klein; Paul Mitchell; Tien Y Wong
Journal:  Arch Ophthalmol       Date:  2008-10

9.  Funduscopy in adult zebrafish and its application to isolate mutant strains with ocular defects.

Authors:  Markus Tschopp; Masanari Takamiya; Kara L Cerveny; Gaia Gestri; Oliver Biehlmaier; Stephen W Wilson; Uwe Strähle; Stephan C F Neuhauss
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

10.  Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy.

Authors:  Thanh T Nguyen; Ryo Kawasaki; Jie Jin Wang; Andreas J Kreis; Jonathan Shaw; Walthard Vilser; Tien Y Wong
Journal:  Diabetes Care       Date:  2009-07-29       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.